Healthcare / Diagnostics & ResearchUpdated 2026-05-10 22:07 UTC

DGX stock hub

Quest Diagnostics is a mature, highly cash-generative leader in the US diagnostic testing market. Its robust national network provides durable scale advantages, supporting consistent free cash flow generation and a reliable, growing dividend. With an implied ~19.4x forward P/E, DGX is positioned as a defensive healthcare compounding asset.

Read full analysis Valuation Archive

Fair value midpoint

$226

$185 - $268

Upside to midpoint

+18.9%

Based on latest report

Confidence

88/100

Data quality and model convergence

Market cap

$21.1B

NYSE

Our take

Research highlights

What our analysis says

Pulled from the latest published report. The full reasoning lives under /analysis.

Biggest opportunity

Bull case

Valuation: Shares are undervalued, supported by a $226.02 composite midpoint tightly aligned with the $223.25 internal valuation anchors.

Biggest risk

Severe PAMA Reimbursement Reset

1-3 Years

Recommended action

Buy

Buy. The current price does not fully reflect the company's structural free cash flow yield and defensive moats. The valuation synthesis, anchored by FCFF and Forward Earnings, justifies an $226.02 fair value.

Market data

Live price

Current market quote for this ticker.

Current price

DGX

In the news

Latest news · DGX

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Analysis map

Jump into the research surface

These links all point into /analysis/*, so a hub rollback leaves the report reader and legacy redirects live.

Forecast

Targets

Bull, base, and bear cases with expected-return framing.

Valuation

Models

Fair-value bridge, DCF, owner earnings, and peer multiples.

Sensitivity

Grid

Cost-of-equity and terminal-growth stress table.

Risks

Bear case

Kill scenarios, soft-pass flags, and downside catalysts.

Earnings

Decision tree

Next earnings setup and beat / inline / miss thresholds.

Position sizing

Checkpoints

Entry, exit, conviction, and quarterly monitoring rules.

Financials

History

Revenue, margins, cash flow, and balance-sheet context.

Peers

Comps

Relative valuation and profitability against the cohort.

Moat

Durability

Economic-profit evidence and competitive advantage risk.

Industry cycle

Context

Sector phase, capital cycle, and secular tailwinds.

Scorecard

Factors

Six-factor overlay and 9-category weighted scorecard.

Recommendation

Verdict

Final action, action steps, opportunity, and biggest risk.

Perspectives

Lenses

Growth, value, and income investor reads.

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E16.3

P25 12.3P50 18.4P75 33.1

Trailing P/E0

P25 14.9P50 23.2P75 38.5

ROE14.5

P25 -105.6P50 -46.5P75 -3.1

ROIC9.3

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Our take

Indicator catalog

All DGX market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

278

Groups with data

Currency

USD

Showing 278 of 278 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001022079
Company name	Quest Diagnostics Incorporated
Country	United States
Country code	US
Cusip	74834L100
Employees	57,000
Employees Change	1,000%
Employees Change Percent	1.79
Enterprise value	$26.8B
Exchange	NYSE
Financial currency	USD
First seen	2026-05-09
In Index	SP500
Industry	Diagnostics & Research
IPO Date	1996-12-17
Isin	US74834L1008
Last refreshed	2026-05-10
Market cap	$20.7B
Market cap category	Large-Cap
Price	$187
Price currency	USD
Rev Per Employee	197,859.65x
Sector	Healthcare
Sic	8071
Symbol	DGX
Website	https://www.questdiagnostics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	4.92%
EV Earnings	26.23x
EV Sales Forward	2.23x
EV/EBIT	16.23x
EV/EBITDA	12.02x
EV/FCF	20.18x
EV/Sales	2.37x
FCF yield	6.39%
Forward P/E	17.11x
P/B ratio	2.82x
P/E ratio	20.71x
P/S ratio	1.84x
PE Ratio10 Y	16.76x
PE Ratio3 Y	19.75x
PE Ratio5 Y	16.64x
PEG ratio	2x
PS Forward	1.73x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	14.62%
EBITDA Margin	19.74%
FCF margin	11.76%
Gross margin	33.28%
Gross Profit	$3.8B
Gross Profit Growth	11.76%
Gross Profit Growth Q	8.63%
Gross Profit Growth3 Y	4.61%
Gross Profit Growth5 Y	-2.51%
Net Income	$1B
Net Income Growth	14.16%
Net Income Growth Q	14.55%
Net Income Growth Quarters	7%
Net Income Growth Years	2%
Net Income Growth3 Y	8.94%
Net Income Growth5 Y	-10.68%
Pretax Margin	12.45%
Profit Margin	9.08%
Profit Per Employee	$17,895
Profitable Years	26
ROA	6.35
Roa5y	7.22
ROCE	11.38
ROE	14.54
Roe5y	18.06
ROIC	9.28
Roic5y	11.34

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	11.67%
Cagr15y	10.39%
Cagr1y	8.05%
Cagr20y	7.91%
Cagr3y	13.37%
Cagr5y	8.26%
Div CAGR10	7.79%
Div CAGR3	6.62%
Div CAGR5	7.23%
EPS Growth	14.45
EPS Growth Q	15.46
EPS Growth Quarters	7
EPS Growth Years	2
EPS Growth3 Y	10.02
EPS Growth5 Y	-7.24
FCF Growth	25.57%
FCF Growth Q	-16.75%
FCF Growth3 Y	15.35%
FCF Growth5 Y	-8.5%
OCF Growth	23.83%
OCF Growth Q	-11.47%
OCF Growth10 Y	7.21%
OCF Growth3 Y	11.57%
OCF Growth5 Y	-5.76%
Revenue Growth	11.03x
Revenue Growth Q	9.16x
Revenue Growth Quarters	9x
Revenue Growth Years	2x
Revenue Growth3 Y	5.51x
Revenue Growth5 Y	1.76x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.69
Assets	$16.7B
Cash	$393M
Current Assets	$2.6B
Current Liabilities	$2.2B
Debt	$6.4B
Debt EBITDA	$2.36
Debt Equity	$0.83
Debt FCF	$4.83
Equity	$7.7B
Interest Coverage	6.11
Liabilities	$8.9B
Long Term Assets	$14.1B
Long Term Liabilities	$6.8B
Net Cash	$-6B
Net Cash By Market Cap	$-29
Net Debt EBITDA	$2.7
Net Debt Equity	$0.78
Net Debt FCF	$4.54
Tangible Book Value	$-3.5B
Tangible Book Value Per Share	$-31.27
WACC	6.51

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	1.18
Inventory Turnover	36.35
Net Working Capital	$673M
Quick ratio	0.91
Working Capital	$389M
Working Capital Turnover	$22.05

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	0.44%
Dividend Growth	6.89%
Dividend Growth Years	14%
Dividend per share	$3.44
Dividend Years	23
Dividend Yield	1.84%
Ex Div Date	2026-04-06
Last Dividend	$0.86
Payout Frequency	Quarterly
Payout Ratio	36.02%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	201.61%
1Y total return	8.04%
200-day SMA	186.9
3Y total return	45.74%
50-day SMA	197.3
50-day SMA vs 200-day SMA	50over200
5Y total return	48.72%
All Time High	213.5
All Time High Change	-12.23%
All Time High Date	2026-02-27
All Time Low	3.31
All Time Low Change	5,556.2%
All Time Low Date	1996-12-18
ATR	4.92
Beta	0.6
Beta1y	-0.12
Beta2y	0.12
Ch YTD	7.99
High	192.2
High52	213.5
High52 Date	2026-02-27
High52ch	-12.23%
Low	186.2
Low52	164.7
Low52 Date	2025-07-15
Low52ch	13.81%
Ma50ch	-5.03%
Price vs 200-day SMA	0.26%
RSI	38.79
RSI Monthly	55.59
RSI Weekly	47.83
Sharpe ratio	0.28x
Sortino ratio	0.7
Total Return	2.28%
Tr YTD	8.95
Tr15y	340.74%
Tr1m	-4.79%
Tr1w	-2.74%
Tr3m	-1.31%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	12
Analyst Count Top	6
Analyst Price Target Top	$218
Analyst Ratings	Buy
Analyst Ratings Top	Buy
Earnings EPS Estimate	$2.36
Earnings EPS Estimate Growth	6.79
Earnings Revenue Estimate	2,820,678,110x
Earnings Revenue Estimate Growth	6.36x
Operating Income	$1.6B
Operating Income Growth	12.87
Operating Income Growth Q	11.99
Operating Income Growth3 Y	6.95
Operating Income Growth5 Y	-8.62
Operating margin	14.62
Price target	$216
Price Target Change	$15.49
Price Target Change Top	$16.51

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	110,080,732%
Float Percent	99.44%
Net Borrowing	-218,000,000
Shares Insiders	0.42%
Shares Institutions	97.79%
Shares Out	110,696,429
Shares Qo Q	0%
Shares Yo Y	-0.44%
Short Float	3.23%
Short Ratio	4.12
Short Shares	3.21

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$1.2B
Average Volume	1,050,539.1x
Bv Per Share	66.36
CAPEX	$-524M
Ch10y	147.3
Ch15y	230.3
Ch1m	-4.79
Ch1w	-2.74
Ch1y	6.13
Ch20y	230.5
Ch3m	-1.74
Ch3y	37.27
Ch5y	34.86
Ch6m	4.4
Change	-1.81%
Change From Open	-2.25
Close	190.8
Days Gap	0.46
Depreciation Amortization	577,000,000
Dollar Volume	142,887,873.2
Earnings Date	2026-04-21
Earnings Time	bmo
EBIT	$1.6B
EBITDA	$2.2B
EPS	$9.05
F Score	7
FCF	$1.3B
FCF EV Yield	4.96x
FCF Per Share	$11.98
Financing CF	-979,000,000
Fiscal Year End	December
Founded	1,967
Goodwill	9,120,000,000
Graham Number	116.24511
Graham Upside	-37.97
Income Tax	$329M
Investing CF	-668,000,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-04-21
Last Report Date	2026-03-31
Last Split Date	2005-06-21
Last Split Type	Forward
Last10k Filing Date	2026-02-26
Lynch Fair Value	$45.25
Lynch Upside	-75.85
Ma150	189.4
Ma150ch	-1.05%
Ma20	194.2
Ma20ch	-3.5%
Net CF	205,000,000
Next Earnings Date	2026-07-21
Open	191.7
Optionable	Yes
P FCF Ratio	15.64
P OCF Ratio	11.21
Payment Date	2026-04-20
Position In Range	19.43
Ppne	2,880,000,000
Price Date	2026-05-08
Price EBITDA	$9.32
Relative Volume	0.73x
Revenue	11,278,000,000x
SBC By Revenue	0.76x
Share Based Comp	86,000,000
Tax By Revenue	2.92x
Tax Rate	23.43%
Tr20y	358.04%
Tr6m	5.33%
Us State	New Jersey
Volume	762,516
Z Score	3.24

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

6.5/10

Business quality stays separate from stock attractiveness.

Forward P/E

16.3x

Valuation uses the full report model stack, not a single multiple.

Next action

Buy

Final action steps are kept in the recommendation tab.

Our take

Income

DGX dividend yield, growth & safety

Yield, payout sustainability, and the multi-year growth streak.

Dividend yield

+1.8%

$3.44 annual per share

Payout ratio

+36.0%

Share of earnings returned as dividends. Below 60% is generally sustainable.

5Y dividend CAGR

+7.2%

14 consecutive years of growth

Total shareholder yield

+2.3%

Next ex-dividend date: 2026-04-06

Performance

DGX stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns DGX?

Insider, institutional, and short-interest positioning.

Institutional ownership

+97.8%

Float: +99.4% of shares outstanding

Insider ownership

+0.4%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

DGX momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

38.8

Neutral momentum band

Price vs 200-day MA

+0.3%

50/200-day relationship not available

Beta (5Y)

0.60

Less volatile than the market

Sharpe ratio

0.28

Risk-adjusted return — higher is better; >1.0 is solid.

Peers

DGX vs. sector cohort

Currency-neutral comparison: P/E, P/S, ROIC, 5Y revenue CAGR, and 1Y total return. Market-cap column appears only when every peer reports in the same currency.

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ABBV	AbbVie Inc.	356.1B	99.3x	5.7x	22.2%	+4.6%	+10.6%	Halten
ABT	Abbott Laboratories	146.9B	23.6x	3.3x	9.6%	+3.9%	-35.8%	Starker Kauf
ACN	Accenture plc	110.8B	14.8x	1.5x	27.2%	+9.6%	-39.5%	Kaufen

Questions

About DGX

Hub-level FAQ points readers to the deeper analysis pages.

What is the current DGX stock rating?

Quest Diagnostics Incorporated is currently shown with Buy in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full DGX analysis?

The full report lives at /stocks/DGX/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for DGX?

The latest report frames DGX around $185 to $268. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the DGX page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.